Trial Profile
Multicentre Randomized Double-Blind Phase II/III Study on the Safety and Immunogenicity of Three Vaccinations With TICOVAC in Two Dosages in Healthy Children Aged Between Six Months and Three Years
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 29 May 2015
Price :
$35
*
At a glance
- Drugs Tick-borne encephalitis vaccine (Primary)
- Indications Encephalitis; Encephalitis virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Baxter Healthcare Corporation; Pfizer